Bo Hansen - SWEDISH ORPHAN Chairman of the Board

BIOVF -- USA Stock  

USD 16.35  0.00  0.00%

  Chairman
Dr. Bo Jesper Hansen M.D. Ph.D. no longer serves as Chairman of the Board of Directors of Swedish Orphan Biovitrum AB effective as of May 24 2016. He has held this position since April 27 2010. He was Member of the Company Board since 2010. He has also served as Member of the Company Nomination Committee and Scientific Committee and Chairman of the Compensation and Benefits Committee. During the course of his career Mr. Hansen has held various positions within Swedish Orphan International AB from 1993 most recently as Chief Executive Officer . He is Founder of Scandinavian Medical Research and has served as Medical Advisor to Synthelabo Pfizer and Yamanouchi. He serves as Member of the Board of Directors of GenSpera Inc. Newron Pharmaceuticals SpA Orphazyme ApS CMC AB Azanta AS Karolinska Development AB and Ablynx NV. He holds a Medical Doctor degree with a Doctor of Philosophy degree from Koebenhavns Universitet.
Age: 57  Chairman Since 2010  Ph.D    
46 86 97 20 00  http://www.sobi.com

Management Efficiency

The company has return on total asset (ROA) of 10.44 % which means that it generated profit of $10.44 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 22.96 % meaning that it generated $22.96 on every $100 dollars invested by stockholders.
The company has accumulated 563K in total debt with debt to equity ratio (D/E) of 39.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. SWEDISH ORPHAN BIOVI has Current Ratio of 0.74 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.

Similar Executives

Showing few of many executives

CHAIRMAN Since

Chinh ChuCatalent
2014
G PrasadDr Reddys Laboratories Ltd
2014
Paul BisaroAllergan plc
2016
Joseph PapaPerrigo Company plc
2015
Amir ElsteinTeva Pharmaceutical Industries
2014
Satish ReddyDr Reddys Laboratories Ltd
2014
Robert CouryMylan NV
2016
Said DarwazahHikma Pharmaceuticals Plc
2018
Mazen DarwazahHikma Pharmaceuticals Plc
2014
Fang YaoSHANGHAI FOSUN PHARMACEUTICAL G
2016
Rodney PiattMylan NV
2011
Marry BrlasPerrigo Company plc
2016
Qiyu ChenSHANGHAI FOSUN PHARMACEUTICAL G
2016
Brenton SaundersAllergan plc
2016
Qi ChenSHANGHAI FOSUN PHARMACEUTICAL G
2012

Entity Summary

Swedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, immunology, and genetic and metabolic diseases. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. SWEDISH ORPHAN is traded on BATS Exchange in USA.SWEDISH ORPHAN BIOVITRUM AB [BIOVF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

SWEDISH ORPHAN BIOVI Leadership Team

Hans Wigzell, Independent Director
Lennart Johansson, Director
Annette Clancy, Independent Director
Paula Treutiger, Head of Communications & Investor Relations
Trista Morrison, Vice President - Communications for North America
Kirsti Gjellan, Senior Vice President Manufacturing Operations
Jorgen Winroth, Head of Investor Relations and VP
Milan Zdravkovic, Senior Vice President Head of Research & Development
Rami Levin, Head of North America
Norbert Oppitz, Head of Specialty Care
Hans Schikan, Independent Director
Dennis Pedersen, Senior Vice President Human Resources
Helena Saxon, Director
Anne Schuermans, Head of Technical Operations
Anders Edvell, Head of Marketing and Sales
Sofiane Fahmy, Head of Southern and Western Europe & North Africa
Philip Wood, Head of Haemophilia
Geoffrey McDonough, CEO
Lars Dreioee, Senior Vice President Chief Quality & Compliance Officer
Alan Raffensperger, COO and Sr. VP
Fredrik Berg, Head of Legal and Intellectual Property, Risk- Safety and Environment Management and General Counsel
Fredrik Wetterlundh, Head of Human Resources
BoGunnar Rosenbrand, Director, Employee Representative
Amy Pott, Head of North America
Adine Axen, Independent Director
Birgitte Volck, Senior Vice President Chief Medical Officer
MatsOlof Wallin, CFO, Senior Vice President
Stefan Fraenkel, Vice President Head of Corporate Development
Hakan Bjorklund, Independent Chairman of the Board
Cecilia Forberg, Vice President Head of Project and Portfolio Management
Stephen James, Vice President Head of Drug Design and Development
Bo Hansen, Chairman of the Board
Armin Reininger, Senior Vice President Head of Global Medical and Scientific Affairs
Hege Hellstrom, Head of EMENAR
Catarina Larsson, Director, Employee Representative
Henrik Stenqvist, CFO
David Allsop, Director
Elisabeth Svanberg, Director
Christian Dreger, Head of Northern Europe, Middle East & Russia
Torbjorn Hallberg, General Counsel and Head of Legal Affairs
Wills HughesWilson, Senior Vice President and Chief Patient Access Officer
Guido Oelkers, President CEO
Pia Axelsson, Director, Employee Representative
Jeffrey Jonas, Independent Director
Matthew Gantz, Director
Theresa Heggie, Independent Director
Pia Axelson, Director, Employee Representative

Stock Performance Indicators

Did you try this?

Run Price Ceiling Movement Now

   

Price Ceiling Movement

Calculate and plot Price Ceiling Movement for different equity instruments
All  Next Launch Module

SWEDISH ORPHAN Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for SWEDISH ORPHAN and Allergan plc. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Search macroaxis.com